Feature | August 30, 2012

Peripheral Vascular Procedures Moving Increasingly to Outpatient Setting

Millennium Research Group’s new physician forum report provides details of physician attitudes and choices

August 30, 2012 — According to Millennium Research Group (MRG), an authority on the medical technology market, as significant numbers of peripheral vascular and vascular access procedures move out of the hospital setting and into a variety of outpatient facilities, manufacturers of peripheral vascular stents, percutaneous transluminal angioplasty (PTA) balloons, atherectomy devices, thrombectomy devices and dialysis catheters will face new and complex challenges in marketing their products.

Physician preference is the main driving force in moving procedures into these facilities. Aside from the increased flexibility in scheduling procedures, physicians are particularly interested in the favorable reimbursement they receive for these procedures. Specialized vascular access centers have sprung up in the past five to 10 years, but many of these procedures are also performed in physician offices and in existing dialysis centers. The range of facility types is wide, making it difficult for manufacturers to target them effectively.

Physicians who run their own centers tend to have limited brand loyalty, but do keep a sharp eye on the bottom line, creating incentives for manufacturers to offer attractive pricing. If manufacturers are to succeed in appealing to this market, they need a deeper understanding of how these physicians acquire information and make purchasing decisions.

These results come from a new MRG report, Outpatient Vascular Treatment Centers Study, part of its Physician Forum series. Physician Forum reports are produced in response to specific market events and trends that are expected to have significant effects on the utilization and sales of medical devices. This report was published in June 2012.

The results are based on surveys that were conducted from March to May 2012 and included 90 respondents in vascular access centers, office-based practices and dialysis centers who have performed a significant number of interventional procedures. Survey respondents were interventional cardiologists, interventional nephrologists, interventional radiologists, nephrologists and vascular surgeons in the United States.

“There is a lot of variation between which procedures different centers and practices will be focusing on in the near future,” said MRG Manager Stephanie LaBelle. “Some are looking to increase their volume of lucrative vein treatments such as varicose vein ablation and sclerotherapy, while others will be specializing in peripheral artery disease, and expanding their atherectomy procedure volumes. Manufacturers need to make sure they have the most updated information on this rapidly changing market.”

Millennium Research Group’s Outpatient Vascular Treatment Centers Study report provides information about physician attitudes and purchase decision criteria for peripheral vascular stents, percutaneous transluminal angioplasty (PTA) balloons, atherectomy devices, thrombectomy devices and dialysis catheters used in vascular access centers, office-based practices and dialysis centers.

For more information: www.MRG.net

Related Content

Sci-image, Scimage, CVIS, CIIMS, Cpacs c-pacs, cardiovascular information system

Today's cardiovascular information systems need to incorporate all facets of the cardiology department, including subspecialties, to allow a complete picture of a patient's record. These data also need to be able to be shared with enterprise data systems, such as the electronic medical record (EMR). This image is from ScImage, illustrating the various aspects that integrate to make up a complete CVIS. 

 

Feature | September 29, 2016 | Val Kapitula, RT(R), PMP, CIIP
Cardiovascular Information and Imaging Systems (CVIS) have existed for many years in the dedicated sub-specialty area
Keystone Heart, TriGuard Embolic Protection Device, real-world results, PCR London Valves Conference 2016
News | Embolic Protection Devices| September 29, 2016
Keystone Heart Ltd. recently announced the safety and efficacy of the TriGuard Cerebral Embolic Protection device...
Neuravi, EmboTrap II stent retriever, thrombectomy device, acute stroke, European launch, CE Mark
News | Thrombectomy Devices| September 28, 2016
Neuravi recently announced Conformité Européenne (CE) Mark approval and launch of the company’s newly available...
Infinix 4D CT

Toshiba's Infinix 4D CT, which combines CT with angiography in the interventional lab.

Feature | Angiography| September 28, 2016 | Tom Watson BS, RCVT, Clinical Analyst, MD Buyline
One of the more significant advancements for interventional X-ray (IXR) in the past few years has been a significantl
TCT 2016, TCT.16, main arena, late breaking trials
Feature | Cath Lab| September 28, 2016
September 28, 2016 — The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 fi
Avinger, U.S. Department of Veterans Affairs, VA, Lumivascular technology, FSS Contract Award
News | Optical Coherence Tomography (OCT)| September 27, 2016
Avinger Inc. recently announced the company has received an FSS Contract Award from the U.S. Department of Veterans...
Bard, Lutonix 014 DCB, drug-coated balloon, six-month endpoint, FDA IDE trial
Technology | Drug-Eluting Balloons| September 26, 2016
C. R. Bard Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE...
smartphones, hospital tranfers, heart attack patients, JACC study, South Korea
News | Mobile Devices| September 23, 2016
Smartphone communication among medical teams at different hospitals can significantly reduce the time it takes for...
Robert M. Califf, FDA commissioner, future of cardiovascular medicine, JACC column
News | Business| September 23, 2016
Technology advances coupled with increased use of social media and personal devices could offer new possibilities for...
Medtronic, In.Pact Admiral drug-coated balloon, trial data, VIVA
News | Drug-Eluting Balloons| September 22, 2016
New data presented at the Vascular Interventional Advances (VIVA) conference demonstrated the durability, consistency...
Overlay Init